U.P. Strauss

638 total citations
14 papers, 505 citations indexed

About

U.P. Strauss is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, U.P. Strauss has authored 14 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Economics and Econometrics. Recurrent topics in U.P. Strauss's work include Renal cell carcinoma treatment (7 papers), Economic and Financial Impacts of Cancer (4 papers) and Cancer Genomics and Diagnostics (4 papers). U.P. Strauss is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Economic and Financial Impacts of Cancer (4 papers) and Cancer Genomics and Diagnostics (4 papers). U.P. Strauss collaborates with scholars based in Germany, United States and France. U.P. Strauss's co-authors include E. Montegriffo, Marc Fellous, Karen Keating, Anna Forsythe, Wei Zhang, Carsten Bokemeyer, Yan Sun, Joachim von Pawel, Kostas Syrigos and Bonne Biesma and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

U.P. Strauss

14 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U.P. Strauss Germany 10 319 238 224 139 65 14 505
Riccardo Ricotta Italy 13 192 0.6× 307 1.3× 165 0.7× 141 1.0× 33 0.5× 37 511
Jie‐Tao Ma China 15 364 1.1× 311 1.3× 198 0.9× 153 1.1× 59 0.9× 43 677
M.S. Gordon United States 14 219 0.7× 212 0.9× 309 1.4× 109 0.8× 80 1.2× 89 686
K. Nathan Sankar United States 14 170 0.5× 269 1.1× 124 0.6× 80 0.6× 36 0.6× 41 526
Yoshiko Umeyama Japan 16 554 1.7× 490 2.1× 263 1.2× 146 1.1× 77 1.2× 35 813
Miah Hiang Tay Singapore 11 207 0.6× 157 0.7× 112 0.5× 76 0.5× 64 1.0× 23 437
R Gray United States 10 272 0.9× 445 1.9× 186 0.8× 313 2.3× 85 1.3× 15 732
Caterina Fontanella Italy 13 196 0.6× 375 1.6× 145 0.6× 139 1.0× 80 1.2× 43 625
Marilyn Mulay United States 11 250 0.8× 365 1.5× 243 1.1× 104 0.7× 45 0.7× 17 644
L. Wood United States 12 333 1.0× 185 0.8× 254 1.1× 126 0.9× 34 0.5× 23 481

Countries citing papers authored by U.P. Strauss

Since Specialization
Citations

This map shows the geographic impact of U.P. Strauss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U.P. Strauss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U.P. Strauss more than expected).

Fields of papers citing papers by U.P. Strauss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U.P. Strauss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U.P. Strauss. The network helps show where U.P. Strauss may publish in the future.

Co-authorship network of co-authors of U.P. Strauss

This figure shows the co-authorship network connecting the top 25 collaborators of U.P. Strauss. A scholar is included among the top collaborators of U.P. Strauss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U.P. Strauss. U.P. Strauss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Forsythe, Anna, et al.. (2020). A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Therapeutic Advances in Medical Oncology. 12. 73 indexed citations
2.
3.
4.
Gore, Martin, Robert J. Jones, Alain Ravaud, et al.. (2016). Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study. British Journal of Urology. 119(6). 846–853. 3 indexed citations
5.
Paz‐Ares, Luis, Bonne Biesma, David F. Heigener, et al.. (2012). Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(25). 3084–3092. 198 indexed citations
6.
Procopio, Giuseppe, Emilio Bajetta, Ulrich Keilholz, et al.. (2011). Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Annals of Oncology. 22(8). 1812–1823. 106 indexed citations
7.
Eisen, Tim, Richard Marais, Annette Affolter, et al.. (2011). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer. 105(3). 353–359. 33 indexed citations
8.
Gore, M., Alain Ravaud, M.A. Kuczyk, et al.. (2011). Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 29(15_suppl). 4609–4609. 20 indexed citations
9.
10.
Staehler, Michael, Giuseppe Procopio, Ulrich Keilholz, et al.. (2009). 254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS). European Urology Supplements. 8(4). 184–184. 2 indexed citations
11.
Beck, J. Thaddeus, et al.. (2009). 7137 Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS). European Journal of Cancer Supplements. 7(2). 434–435. 9 indexed citations
12.
Bracarda, Sergio, Giuseppe Procopio, Ulrich Keilholz, et al.. (2009). 142 ELDERLY PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)SUCCESSFULLY TREATED. European Urology Supplements. 8(4). 156–156. 2 indexed citations
13.
Susilo, Rudy, et al.. (2006). Nail Penetration of Sertaconazole with a Sertaconazole-Containing Nail Patch Formulation. American Journal of Clinical Dermatology. 7(4). 259–262. 17 indexed citations
14.
Susilo, Rudy, Hans Christian Körting, & U.P. Strauss. (2003). Dermatomycoses of the Glabrous Skin. Clinical Drug Investigation. 23(6). 387–394. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Riccardo Ricotta Breakdown of academic impact, for papers by Jie‐Tao Ma Breakdown of academic impact, for papers by M.S. Gordon Breakdown of academic impact, for papers by K. Nathan Sankar Breakdown of academic impact, for papers by Yoshiko Umeyama Breakdown of academic impact, for papers by Miah Hiang Tay Breakdown of academic impact, for papers by R Gray Breakdown of academic impact, for papers by Caterina Fontanella Breakdown of academic impact, for papers by Marilyn Mulay Breakdown of academic impact, for papers by L. Wood
Rankless by CCL
2026